Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR) T-cell therapy has achieved success in B-cell leukemias by targeting the CD19 antigen.
• However, CAR T-cell efficacy is limited in B-cell lymphomas and solid tumors due to poor T-cell infiltration and immunosuppressive tumor microenvironments.

Discussion:

• This review explores methods to overcome challenges in applying CAR T-cell therapy to solid tumors.
• Strategies include enhancing CAR T-cell resistance to the tumor microenvironment and modifying the tumor microenvironment to be less immunosuppressive.
• Inducing bystander immunity is also discussed as a means to improve therapeutic outcomes.

Key Insights:

• Lymphoma and solid tumor microenvironments present significant barriers to CAR T-cell therapy.
• CAR T-cells require modifications to effectively infiltrate and function within these challenging tumor types.
• Overcoming immune suppression and improving T-cell persistence are critical for advancing CAR T-cell therapy.

Outlook:

• Future research should focus on engineering CAR T-cells with improved tumor infiltration capabilities.
• Developing combination therapies that target both CAR T-cells and the tumor microenvironment is essential.
• Further investigation into inducing robust bystander immune responses will be key for durable responses in solid tumors.